Most drugs for rare diseases do have extraordinary costs associated with them by the time they get to the patient, mainly on the small target market - why the real gold ticket is PBS as most of the time unaffordable to many without it.
Biogen's Spinraza for SMA approved last year - $125K a dose and needs 6 doses in the first year and 3 in each year thereafter - so that's $725K in year 1 & $375K from year 2.
Sarepta's Eteplirsen for DMD approved last year $300K a year.
The average cost to patient of rare disease drugs is well over $100K a year though.
Ann: Half Yearly Report and Accounts, page-22
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 3429 | 4 |
View Market Depth
| Last trade - 16.16pm 08/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable